The C.A.M. Report
Complementary and Alternative Medicine: Fair, Balanced, and to the Point
  • About this web log

    This blog ran from 2006 to 2016 and was intended as an objective and dispassionate source of information on the latest CAM research. Since my background is in pharmacy and allopathic medicine, I view all CAM as advancing through the development pipeline to eventually become integrated into mainstream medical practice. Some will succeed while others fail. But all are treated fairly here.

  • About the author

    John Russo, Jr., PharmD, is president of The MedCom Resource, Inc. Previously, he was senior vice president of medical communications at, a complementary and alternative medicine website.

  • Common sense considerations

    The material on this weblog is for informational purposes. It is not medical advice or counsel. Be smart, consult your health professional before using CAM.

  • Recent Posts

  • Recent Comments

    Safety of probiotics and the translocation issue

    Probiotics are increasingly being used for their health benefits and are advocated by many healthcare professionals.

    So, what’s the problem?

    The intestinal mucosa acts as a defense barrier that prevents bacteria in the gut from invading organs and tissues. Under certain circumstances these bacteria can pass through the mucosal barrier to infect lymph nodes and systemic organs via a process termed bacterial translocation.

    Dr. Min-Tze Liong from Universiti Sains Malaysia says that due to the safety record of probiotics and their confusion with pathogenic bacteria, probiotics are often overlooked as contaminants and potential pathogens.

    The evidence base for their use in specific clinical scenarios is strong, but they are commonly used in a much wider range of scenarios in which their efficacy is not well established.

    Researchers from the University of Melbourne in Victoria, Australia tell us “Probiotics are safe for use in otherwise healthy persons, but should be used with caution in some persons because of the risk of sepsis. Newly developed probiotic strains should be thoroughly evaluated for safety before being marketed.”

    They continue, “It is clear that different strains can have very specific effects. Moreover their effects may vary in health and disease, in different disease states, and in different age groups. Thus, clinical trial results from one probiotic strain in one population cannot be automatically generalized to other strains or to different populations.”

    The bottom line?
    “Probiotic translocation and infection deserve further investigation,” according to Dr. Liong, “and should become a facet of safety assessment so the negative effects of probiotics do not outweigh the benefits.”

    4/13/08 15:40 JR

    Leave a Comment

    You must be logged in to post a comment.